Compare Stocks: QNTM, PYPD, NTRB, and MIST

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
MIST Milestone Pharmaceuticals	$0.81 -0.7%	$1.05	$0.75 ▼ $3.06	$100.81M	1.01	1.38 million shs	768,303 shs
NTRB Nutriband	$7.28 -1.1%	$5.15	$2.80 ▼ $9.19	$88.50M	1.92	143,335 shs	46,944 shs
PYPD PolyPid	$5.19 -3.4%	$4.98	$3.06 ▼ $5.73	$99.04M	1.38	81,616 shs	167,717 shs
QNTM Quantum Biopharma	$3.44 +0.6%	$3.36	$2.07 ▼ $19.00	$27.82M	0.39	201,290 shs	79,227 shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
MIST Milestone Pharmaceuticals	0.00%	+2.70%	-33.08%	-38.66%	-60.50%
NTRB Nutriband	0.00%	-9.00%	+29.31%	+137.91%	+0.14%
PYPD PolyPid	0.00%	-0.57%	-1.52%	+3.39%	+54.01%
QNTM Quantum Biopharma	0.00%	-10.65%	+16.61%	-1.99%	-79.19%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
MIST Milestone Pharmaceuticals	$0.81 -0.7%	$1.05	$0.75 ▼ $3.06	$100.81M	1.01	1.38 million shs	768,303 shs
NTRB Nutriband	$7.28 -1.1%	$5.15	$2.80 ▼ $9.19	$88.50M	1.92	143,335 shs	46,944 shs
PYPD PolyPid	$5.19 -3.4%	$4.98	$3.06 ▼ $5.73	$99.04M	1.38	81,616 shs	167,717 shs
QNTM Quantum Biopharma	$3.44 +0.6%	$3.36	$2.07 ▼ $19.00	$27.82M	0.39	201,290 shs	79,227 shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
MIST Milestone Pharmaceuticals	0.00%	+2.70%	-33.08%	-38.66%	-60.50%
NTRB Nutriband	0.00%	-9.00%	+29.31%	+137.91%	+0.14%
PYPD PolyPid	0.00%	-0.57%	-1.52%	+3.39%	+54.01%
QNTM Quantum Biopharma	0.00%	-10.65%	+16.61%	-1.99%	-79.19%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
MIST Milestone Pharmaceuticals	2.71	Moderate Buy	$6.40	690.42% Upside
NTRB Nutriband	1.50	Reduce	N/A	N/A
PYPD PolyPid	2.50	Moderate Buy	$11.33	118.37% Upside
QNTM Quantum Biopharma	2.00	Hold	$8.00	132.56% Upside

Current Analyst Ratings Breakdown

Latest QNTM, PYPD, NTRB, and MIST Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/28/2026	NTRB Nutriband	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
9/18/2026	PYPD PolyPid	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
9/3/2026	MIST Milestone Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/31/2026	QNTM Quantum Biopharma	Rodman & Renshaw Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$8.00
8/21/2026	QNTM Quantum Biopharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/20/2026	MIST Milestone Pharmaceuticals	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$3.00
7/22/2026	PYPD PolyPid	Craig Hallum Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$12.00
7/21/2026	PYPD PolyPid	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$13.00
7/14/2026	MIST Milestone Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/13/2026	MIST Milestone Pharmaceuticals	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold

(Data available from 10/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
MIST Milestone Pharmaceuticals	$1.55M	65.04	N/A	N/A	$0.39 per share	2.08
NTRB Nutriband	$2.04M	43.39	N/A	N/A	$0.44 per share	16.55
PYPD PolyPid	N/A	N/A	N/A	N/A	$0.69 per share	N/A
QNTM Quantum Biopharma	N/A	N/A	N/A	N/A	$1.34 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
MIST Milestone Pharmaceuticals	-$63.06M	-$0.69	N/A	N/A	N/A	N/A	-288.33%	-58.27%	11/11/2026 (Estimated)
NTRB Nutriband	-$8.23M	-$0.53	N/A	N/A	N/A	-430.35%	-109.07%	-95.54%	12/7/2026 (Estimated)
PYPD PolyPid	-$34.17M	-$1.48	N/A	N/A	N/A	N/A	-311.08%	-150.83%	11/11/2026 (Estimated)
QNTM Quantum Biopharma	-$26.17M	-$5.49	N/A	N/A	N/A	N/A	-582.23%	-184.20%	11/6/2026 (Estimated)

Latest QNTM, PYPD, NTRB, and MIST Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
9/4/2026	Q2 2027	NTRB Nutriband	N/A	-$0.07	N/A	-$0.07	N/A	$0.44 million
8/13/2026	Q2 2026	QNTM Quantum Biopharma	-$0.4116	-$0.47	-$0.0584	-$0.47	N/A	N/A
8/12/2026	Q2 2026	MIST Milestone Pharmaceuticals	-$0.1950	-$0.21	-$0.0150	-$0.21	$0.82 million	$0.56 million
8/12/2026	Q2 2026	PYPD PolyPid	-$0.3775	-$0.35	+$0.0275	-$0.35	$0.30 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
MIST Milestone Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
NTRB Nutriband	N/A	N/A	N/A	N/A	N/A
PYPD PolyPid	N/A	N/A	N/A	N/A	N/A
QNTM Quantum Biopharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
MIST Milestone Pharmaceuticals	3.25	8.13	7.92
NTRB Nutriband	N/A	4.21	4.02
PYPD PolyPid	N/A	1.35	1.35
QNTM Quantum Biopharma	N/A	1.20	1.19

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
MIST Milestone Pharmaceuticals	86.18%
NTRB Nutriband	19.70%
PYPD PolyPid	26.47%
QNTM Quantum Biopharma	1.24%

Insider Ownership

Company	Insider Ownership
MIST Milestone Pharmaceuticals	5.03%
NTRB Nutriband	52.21%
PYPD PolyPid	24.70%
QNTM Quantum Biopharma	8.53%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
MIST Milestone Pharmaceuticals	38	124.50 million	118.24 million	Optionable
NTRB Nutriband	3	12.16 million	5.81 million	Not Optionable
PYPD PolyPid	75	19.08 million	14.37 million	No Data
QNTM Quantum Biopharma	7	8.09 million	7.40 million	N/A

QNTM, PYPD, NTRB, and MIST Headlines

Recent News About These Companies

IBN Announces Latest Episode of The BioMedWire Podcast Featuring the Return of Anthony Durkacz, Executive Co-Chair of Quantum BioPharma Ltd.

September 30, 2026 | globenewswire.com

Quantum BioPharma (QNTM) Receives FDA Green Light to Move Lucid-MS Into Phase 2 Testing

September 25, 2026 | finance.yahoo.com

Quantum BioPharma Licensee Unbuzzd Taps New CEO Ahead of Planned Listing

September 25, 2026 | theglobeandmail.com

Quantum BioPharma (NASDAQ: QNTM) Receives FDA Green Light to Move Lucid-MS into Phase 2 Testing

September 25, 2026 | markets.businessinsider.com

Quantum Biopharma Licensee Unbuzzd Wellness to Advance Clinically Validated Alcohol Metabolism Accelerant After Appointing Zappy as CEO

September 24, 2026 | globenewswire.com

Quantum BioPharma (QNTM) Pursues a New Path for Better Multiple Sclerosis Treatments

September 23, 2026 | finance.yahoo.com

Quantum BioPharma (NASDAQ: QNTM) Pursues a New Path for Better Multiple Sclerosis Treatments

September 23, 2026 | markets.businessinsider.com

Quantum Biopharma (NASDAQ:QNTM) Shares Up 2.5% - Here's Why

September 23, 2026 | americanbankingnews.com

Quantum BioPharma Ltd. (NASDAQ: QNTM) Pursues a New Path for Better Multiple Sclerosis Treatments

September 22, 2026 | streetinsider.com

Quantum BioPharma (NASDAQ: QNTM) Announces that Rodman & Renshaw Initiates Coverage with Buy Rating, $8 Price Target

September 17, 2026 | markets.businessinsider.com

Rodman & Renshaw Initiates Analyst Coverage on Quantum BioPharma with a BUY Rating and US$8 Price Target

September 17, 2026 | globenewswire.com

Quantum BioPharma (QNTM) to Present at 3rd Annual ArcStone-Kingswood Growth Summit

September 15, 2026 | finance.yahoo.com

Quantum BioPharma (NASDAQ: QNTM) to Present at 3rd Annual ArcStone-Kingswood Growth Summit

September 15, 2026 | markets.businessinsider.com

Quantum BioPharma to Attend the ArcStone-Kingswood Growth Summit 2026 in Toronto

September 15, 2026 | newsfilecorp.comN

NetworkNewsAudio Announces Audio Press Release (APR) Discussing FDA Clearance for Trial of First-in-Class Treatment Creating ‘Rare Moment’ in MS Research

September 14, 2026 | theglobeandmail.com

NetworkNewsAudio Announces Audio Press Release (APR) Discussing FDA Clearance for Trial of First-in-Class Treatment Creating ‘Rare Moment' in MS Research

September 14, 2026 | globenewswire.com

Quantum BioPharma Ltd. (NASDAQ: QNTM) Filling Key Gap in MS Treatment, Cleared by FDA to Launch Historic Trials

September 11, 2026 | globenewswire.com

Quantum BioPharma Receives FDA Clearance For Lucid-MS Phase 2 Trial

September 9, 2026 | rttnews.com

Quantum BioPharma Ltd. NASDAQ: QNTM) Receives FDA Clearance to Begin Trials for Historic MS Treatment

September 9, 2026 | globenewswire.com

Quantum BioPharma Announces Plans to Voluntarily Delist its Class B Shares from the Canadian Securities Exchange

September 1, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

QNTM, PYPD, NTRB, and MIST Company Descriptions

Milestone Pharmaceuticals NASDAQ:MIST

$0.81 -0.01 (-0.74%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$0.81 0.00 (-0.33%)

As of 10/2/2026 07:38 PM Eastern

Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans, as well as with the Montreal Heart Institute, the WCN network, and other research centers. The company was incorporated in 2003 and is headquartered in Montréal, Canada.

Nutriband NASDAQ:NTRB

$7.28 -0.08 (-1.09%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$7.43 +0.15 (+2.02%)

As of 10/2/2026 07:57 PM Eastern

Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. Its lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. The company also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility. It has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices; and Kindeva Drug Delivery, L.P. to develop AVERSAL Fentanyl based on its proprietary AVERSAL abuse deterrent transdermal technology. The company was incorporated in 2016 and is headquartered in Orlando, Florida.

PolyPid NASDAQ:PYPD

$5.19 -0.18 (-3.35%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$5.16 -0.03 (-0.48%)

As of 10/2/2026 07:30 PM Eastern

PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. It is also developing OncoPLEX, for the treatment of intra-tumoral cancer. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.

Quantum Biopharma NASDAQ:QNTM

$3.44 +0.02 (+0.58%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$3.40 -0.04 (-1.02%)

As of 10/2/2026 07:31 PM Eastern

Quantum Biopharma Ltd. is a biotechnology pharmaceutical research and development company, which focuses on the cultivation, process, and sale of medical cannabis. It operates through the Biotechnology and Strategic Investments segments. The Biotechnology segment is involved in the research and development of the company's three drug candidates consisting of FSD-PEA, Lucid-PSYCH, and Lucid-MS. The Strategic Investments segment is focused on generating returns and cashflow through the issuance of loans secured by residential or commercial property. The company was founded by Thomas Fairfull, Zeeshan Saeed and Anthony J. Durkacz on October 20, 1994 and is headquartered in Toronto, Canada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest QNTM, PYPD, NTRB, and MIST Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest QNTM, PYPD, NTRB, and MIST Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

QNTM, PYPD, NTRB, and MIST Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

QNTM, PYPD, NTRB, and MIST Company Descriptions

Milestone Pharmaceuticals NASDAQ:MIST

Nutriband NASDAQ:NTRB

PolyPid NASDAQ:PYPD

Quantum Biopharma NASDAQ:QNTM

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest QNTM, PYPD, NTRB, and MIST Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest QNTM, PYPD, NTRB, and MIST Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

QNTM, PYPD, NTRB, and MIST Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

QNTM, PYPD, NTRB, and MIST Company Descriptions

Milestone Pharmaceuticals NASDAQ:MIST

Nutriband NASDAQ:NTRB

PolyPid NASDAQ:PYPD

Quantum Biopharma NASDAQ:QNTM

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools